Koji Mikami

Nishinomiya-hama, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.

Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.

Journal: Anticancer research
Published: February 28, 2026

Real-world effectiveness and safety of adjuvant atezolizumab in pathological stage IIA-IIIB non-small cell lung cancer following curative surgery.

Real-world effectiveness and safety of adjuvant atezolizumab in pathological stage IIA-IIIB non-small cell lung cancer following curative surgery.

Journal: Journal of thoracic disease
Published: December 08, 2025

Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Journal: International journal of clinical oncology
Published: May 05, 2025

Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.

Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.

Journal: Clinical lung cancer
Published: April 30, 2025

Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.

Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.

Journal: Targeted oncology
Published: April 08, 2025

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 21, 2024

Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study.

Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study.

Journal: Oncology
Published: October 09, 2024

Clinical Significance of Bone Metastases in Pleural Mesothelioma.

Clinical Significance of Bone Metastases in Pleural Mesothelioma.

Journal: Thoracic cancer
Published: September 27, 2024

KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.

KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.

Journal: Cancer science
Published: August 23, 2024

Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.

Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 16, 2023

Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies.

Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies.

Journal: eNeurologicalSci
Published: November 05, 2021

Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.

Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.

Journal: Cancer science
Published: January 17, 2020
Showing 1-12 of 43

Last Updated: 09/26/2026